Loading…
Loading…
CLVR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CLVR and 80,000+ other tickers.
See exactly how CLVR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLVR and 80,000+ other tickers.
Clever Leaves Holdings Inc. is a company primarily focused on the cannabis sector. Its operations are structured into two distinct divisions: Cannabinoid and Non-Cannabinoid. The Cannabinoid segment oversees the global cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid-based products. In contrast, the Non-Cannabinoid segment, operating within the United States, specializes in the formulation, production, marketing, sales, and delivery of a diverse array of nutraceuticals, natural remedies, wellness items, detoxification solutions, and various…
Palatin Technologies (PINK: PTNT - Get Free Report) and Clever Leaves (NASDAQ: CLVR - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Palatin Technologies and
TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, today announced that its Board of Directors (the “Board”) determined to voluntarily delist its common shares, without par value (the “common shares”) and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the “Warrants” and together with the common shares, the “Securities”) from The Nasdaq Stock Market LLC (“Nasdaq”) and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).
- 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US dollars unless otherwise indicated.
As the cannabis industry continues to flourish in the United States, investors are keenly watching the market for top-performing marijuana stocks. With the industry projected to reach a staggering $30 billion by 2025, the allure of double-digit gains before March is strong. Recent updates on federal legalization efforts have further invigorated the market. These developments promise to expand the industry's legal framework, potentially unlocking vast untapped markets. Investors are advised to employ technical analysis and proper risk management strategies. These tools are crucial for navigating the volatile cannabis sector. They help identify promising entry and exit points, maximizing returns while minimizing risks.
TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves' facility in order to register market-leading cultivars for production and commercialization.